Announcements Trials
Browse Landscape

Phase

Phase NA 32Phase EARLY_PHASE1 2Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Lymphoma 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Rectal Neoplasms 1Pain 1Neoplasms 1Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Lymphedema 1Glioma 1Fallopian Tube Neoplasms 1Carcinoma in Situ 1Brenner Tumor 1Breast Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1Abnormalities, Radiation-Induced 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Methods × Clear all
NCT01272024 2016-06-15

TEAMS

Yale University

Phase 3 Completed
146 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡